Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LOS ANGELES, MARCH 27, 2026 (GLOBE NEWSWIRE) -- THE PORTNOY LAW FIRM ADVISES DISC MEDICINE, INC. (DISC MEDICINE" OR THE "COMPANY") (NASDAQ: IRON) INVESTORS THAT THE FIRM HAS INITIATED AN INVESTIGATION INTO POSSIBLE SECURITIES FRAUD, AND MAY FILE A CLASS ACTION ON BEHALF OF INVESTORS.

DISC MEDICINE, INC. INVESTIGATED BY THE PORTNOY LAW FIRM

WATERTOWN, MASS., MARCH 26, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED THAT THE LAST PARTICIPANT HAS BEEN RANDOMIZED AND DOSED IN THE PIVOTAL PHASE 3 APOLLO TRIAL OF BITOPERTIN IN EPP. ORIGINALLY PLANNED AS AN N=150 STUDY, THE STUDY WAS EXPANDED TO 183 PARTICIPANTS DUE TO PATIENT AND PHYSICIAN DEMAND.

DISC MEDICINE ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 3 APOLLO TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA

NEW YORK, MARCH 26, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. ("DISC" OR THE "COMPANY") (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. - IRON

INVESTIGATION EXAMINES GAP BETWEEN REPORTED FIGURES AND GAAP RESULTS AT DISC MEDICINE AHEAD OF ITS 21.9% STOCK COLLAPSE NEW YORK, MARCH 25, 2026 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP IS INVESTIGATING WHETHER DISC MEDICINE, INC. (NASDAQ: IRON) AND CERTAIN OF ITS OFFICERS FULFILLED THEIR DISCLOSURE OBLIGATIONS TO INVESTORS IN THE PERIOD LEADING UP TO THE COMPANY'S ANNOUNCEMENT OF A COMPLETE RESPONSE LETTER FROM THE FDA. SHAREHOLDERS WHO PURCHASED IRON SHARES AND INCURRED LOSSES MAY OBTAIN FURTHER INFORMATION BY CONTACTING LEVI & KORSINSKY.

IRON INVESTORS LOSE UP TO $22/SHARE -- LEVI & KORSINSKY, LLP INVESTIGATES DISC MEDICINE

NEW YORK, MARCH 24, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COM OR 646-581-9980, EXT. 7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. IRON

NEW YORK, MARCH 24, 2026 (GLOBE NEWSWIRE) -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

IRON INVESTOR NEWS: IF YOU HAVE SUFFERED LOSSES IN DISC MEDICINE, INC. (NASDAQ: IRON), YOU ARE ENCOURAGED TO CONTACT THE ROSEN LAW FIRM ABOUT YOUR RIGHTS

NEW YORK, MARCH 21, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT IT IS INVESTIGATING POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

DISC MEDICINE INVESTORS WHO LOST MONEY AFTER THE FDA ISSUED A COMPLETE RESPONSE LETTER FOR BITOPERTIN ARE ENCOURAGED TO CONTACT LEVI & KORSINSKY NEW YORK, MARCH 18, 2026 /PRNEWSWIRE/ -- LEVI &KORSINSKY, LLP IS INVESTIGATING DISC MEDICINE, INC. (NASDAQ: IRON) REGARDING WHETHER THE COMPANY ADEQUATELY COMMUNICATED RISKS REGARDING ITS BITOPERTIN PROGRAM BEFORE THE FDA'S ISSUANCE OF A COMPLETE RESPONSE LETTER ON FEBRUARY 13, 2026, WHICH CAUSED A 21.9% DECLINE IN SHARE PRICE. INVESTORS WHO SUFFERED LOSSES ON IRON STOCK MAY CLICK HERE FOR ADDITIONAL INFORMATION ABOUT THIS INVESTIGATION.

IRON DROPS UP TO 39% AFTER FDA CRL FOR BITOPERTIN -- LEVI & KORSINSKY, LLP INVESTIGATES

INVESTIGATION EXAMINES GAP BETWEEN REPORTED FIGURES AND GAAP RESULTS AT DISC MEDICINE AHEAD OF ITS 21.9% STOCK COLLAPSE NEW YORK, MARCH 11, 2026 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP IS INVESTIGATING WHETHER DISC MEDICINE, INC. (NASDAQ: IRON) AND CERTAIN OF ITS OFFICERS FULFILLED THEIR DISCLOSURE OBLIGATIONS TO INVESTORS IN THE PERIOD LEADING UP TO THE COMPANY'S ANNOUNCEMENT OF A COMPLETE RESPONSE LETTER FROM THE FDA. SHAREHOLDERS WHO PURCHASED IRON SHARES AND INCURRED LOSSES MAY OBTAIN FURTHER INFORMATION BY CONTACTING LEVI & KORSINSKY.

NEW YORK, FEB. 26, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC.("DISC" OR THE "COMPANY") (NASDAQ: IRON).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC.- IRON

WATERTOWN, MASS., FEB. 26, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A REVIEW OF RECENT PROGRAM AND CORPORATE DEVELOPMENTS.

DISC MEDICINE REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, FEB. 24, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORSOFDISC MEDICINE, INC.- IRON

NEW YORK, FEB. 19, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. ("DISC" OR THE "COMPANY") (NASDAQ: IRON).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK, FEB. 17, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

WATERTOWN, MASS., FEB. 13, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TODAY ISSUED A COMPLETE RESPONSE LETTER (CRL) FOR THE NEW DRUG APPLICATION (NDA) FOR BITOPERTIN AS A TREATMENT FOR PATIENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP). BITOPERTIN HAS BEEN UNDER REVIEW FOR ACCELERATED APPROVAL AND AS PART OF THE COMMISSIONER'S NATIONAL PRIORITY VOUCHER (CNPV) PILOT PROGRAM.

DISC MEDICINE RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR BITOPERTIN FOR THE TREATMENT OF EPP

NEW YORK, FEB. 12, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. ("DISC" OR THE "COMPANY") (NASDAQ: IRON).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK, FEB. 03, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. (DISC OR THE COMPANY) (NASDAQ: IRON).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

NEW YORK, JAN. 29, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF DISC MEDICINE, INC. ("DISC" OR THE "COMPANY") (NASDAQ: IRON).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

Disc Medicine, Inc.

IRON

Price

Financial Reports

No items found.

Press Releases

Disc Medicine, Inc.

IRON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IRON